S1P receptor antagonists fingolimod and siponimod do not improve the outcome of experimental autoimmune myasthenia gravis mice after disease onset
Sign Up to like & getrecommendations! Published in 2018 at "European Journal of Immunology"
DOI: 10.1002/eji.201747187
Abstract: Myasthenia gravis (MG) is an autoimmune disease characterized by muscle weakness and fatigue in the presence of circulating antibodies against components of the neuromuscular junction. Most patients have a good prognosis, but some are refractory… read more here.
Keywords: experimental autoimmune; autoimmune myasthenia; myasthenia gravis; fingolimod siponimod ... See more keywords